文献速递临床试验与 GCP流行病学与生物统计

在革兰阴性菌血症受试者中比较快速抗生素敏感性检测与标准检测血液培养评估结果的多中心多国前瞻性随机对照试验研究方案:FAST试验

Study protocol for a multicenter, multinational prospective randomized controlled trial comparing outcomes in subjects with Gram-negative bacteremia who have blood culture evaluation using Fast Antibiotic Susceptibility Testing vs. standard of care testing: the FAST trial.
PubMed 文献 · Trials · 2025-11-12

FAST试验是一项在希腊、印度、以色列和西班牙开展的两臂、多中心、多国前瞻性随机对照试验,计划纳入900例血培养生长革兰阴性杆菌的住院受试者,按1:1随机接受标准抗生素敏感性检测或快速表型抗生素敏感性检测VITEK REVEAL™联合标准检测,并由抗菌药物管理临床医生审核建议调整治疗。主要结局为三分类结局期望排序(DOOR),关键次要结局包括死亡率、住院时长和随机化后3天内抗生素升级或降级时间。

要点

  • 在抗生素耐药率高国家开展多中心前瞻性随机对照试验,比较快速表型AST与标准AST对革兰阴性菌血症结局的影响。
  • 计划随机900例血培养生长革兰阴性杆菌的住院受试者,1:1分配至VITEK REVEAL™联合标准AST组或标准AST组。
  • 主要结局为三分类DOOR(无不良事件存活、至少一个不良事件存活、死亡),主要分析基于改良意向治疗人群。

核心结论

  • 该试验将评估在抗生素耐药率高的临床环境中,使用快速表型AST方法是否较常规方法改善革兰阴性血流感染患者的结局。

研究设计与样本

  • 两臂、多中心、多国前瞻性随机对照临床试验,在希腊、印度、以色列和西班牙等抗生素耐药率高的国家开展,计划纳入900例因常规临床诊疗采集血培养且生长革兰阴性杆菌的住院受试者。
  • 受试者按1:1随机分配至标准抗生素敏感性检测组或快速表型AST方法VITEK REVEAL™联合标准AST组,两组均由抗菌药物管理临床医生审核并在有指征时建议调整抗生素治疗。
  • 主要分析在改良意向治疗人群中进行。

关键数值与推荐

  • 主要结局为三分类结局期望排序(DOOR),定义为三个有序等级:无不良事件存活、至少一个不良事件存活、死亡。
  • 关键次要结局包括死亡率、住院时长和随机化后3天内抗生素升级或降级时间。
  • 探索性结局包括五分类DOOR、VITEK REVEAL™与标准检测的分类一致性、临床医生对抗菌药物管理建议的依从性,以及基于抗生素谱、活性和血流分离株敏感性特征的治疗选择期望度(DOOR MAT)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Novel, rapid blood culture diagnostics can provide faster antibiotic susceptibility results (AST) compared to standard methods but their impact on clinical outcomes is unclear and not assessed in many prospective clinical trials. METHODS: This study is a two-arm, multicenter, multinational, prospective randomized controlled clinical trial conducted in countries with high antibiotic resistance rates including Greece, India, Israel, and Spain. Nine hundred hospitalized subjects who have blood cultures collected as part of routine clinical care with growth of Gram-negative bacilli (GNB) will be randomized 1:1 to blood culture evaluation using standard of care (SOC) AST vs. a rapid phenotypic AST method, VITEK REVEAL™ in addition to SOC AST. Subjects in both study arms will be reviewed by antibiotic stewardship clinicians who will recommend changes to antibiotic therapy, if indicated. The primary outcome is a composite three-category Desirability of Outcome Ranking (DOOR) defined using three ordered levels: alive without deleterious events, alive with at least one deleterious event, and death. Key secondary outcomes include mortality, length of stay, and time to antibiotic escalation or de-escalation within 3 days of randomization. Exploratory outcomes include a five-category DOOR, categorial agreement between VITEK REVEAL™ and SOC testing, clinician compliance with antibiotic stewardship recommendations, and desirability of treatment selection based on antibiotic spectrum, activity, and bloodstream isolate susceptibility profile (DOOR MAT). The primary analysis will be conducted on the modified intention-to-treat population. DISCUSSION: This trial will evaluate whether use of a rapid phenotypic AST method improves outcomes compared to use of conventional methods for patients with Gram-negative bloodstream infections in clinical settings with high antibiotic resistance rates. TRIAL REGISTRATION: ClinicalTrials.gov ID NCT06174649. Registered on Dec 18 2023. PROTOCOL VERSION: Number 20-0021, version 5.0, 11-April-2024.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Banerjee R, Komarow L, Li Y, et al. Study protocol for a multicenter, multinational prospective randomized controlled trial comparing outcomes in subjects with Gram-negative bacteremia who have blood culture evaluation using Fast Antibiotic Susceptibility Testing vs. standard of care testing: the FAST trial. Trials. 2025. PMID: 41225518. doi:10.1186/s13063-025-09228-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。